ATAI Life Sciences N.V. (ATAI) News
Filter ATAI News Items
ATAI News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ATAI News Highlights
- ATAI's 30 day story count now stands at 2.
- Over the past 27 days, the trend for ATAI's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about ATAI are DRUG and TAP.
Latest ATAI News From Around the Web
Below are the latest news stories about ATAI LIFE SCIENCES NV that investors may wish to consider to help them evaluate ATAI as an investment opportunity.
GH Research Drags Down Psychedelic Drug Stocks Index By 7%The 5 constituents in the Psychedelic Drug Stocks Index continue to exhibit extreme volatility week after week. |
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline HighlightsPhase 2b study of RL-007 in CIAS patients continues to be on track to report data in 2H 2024 and data from the EMP-01 (MDMA derivative) Phase 1 study is anticipated to report out later this year. Phase 1 data of VLS-01 (a proprietary oral transmucosal film formulation of DMT) demonstrated that 160mg of VLS-01 reached exposure levels comparable to 30mg of IV DMT. Acceptance of three non-clinical poster presentations at upcoming medical meetings, including non-clinical data for RL-007 and two nove |
Weekly Roundup on the Cannabis Sector & Psychedelic SectorKey Takeaways; Cannabis Sector Trulieve is challenging 280E cannabis taxation, seeking $143 million federal tax refund. TerrAscend raised its full year 2023 guidance, triggering a surge in stock price. Red White & Bloom won the race to acquire Aleafia Health after an earlier stumble. Key Takeaways; Psychedelic Sector Atai strengthened investment in IntelGenx technologies. Awakn’s […] |
ATAI LIFE SCIENCES ANNOUNCES FILING OF EARLY WARNING REPORTThis press release is being issued pursuant to National Instrument 62-103 – The Early Warning System and Related Take-Over Bid and Insider Reporting Issues ("NI 62-103"), in connection with certain transactions completed by atai Life Sciences AG (Nasdaq: ATAI) ("atai") and IntelGenx Technologies Corp. (the "IntelGenx"), that were previously described in a press release issued by IntelGenx on August 31 2023. |
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro SummitNEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023. Details of the company’s participation is as follows: Jefferies Inaugural Biotech CNS/Neuro Summit Format: Fireside Chat Date and Time: Wednesday, October 11th at 8:30 A.M. ET Location: New |
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy ParticipantsVLS-01, a proprietary oral transmucosal film (OTF) formulation of DMT, was well-tolerated with a favorable safety profilePharmacokinetic and pharmacodynamic data confirmed systemic delivery of DMT via the oral, transmucosal route at levels comparable to those achieved with IV administrationCompany plans to further optimize VLS-01 in preparation for a Phase 2 study in treatment-resistant depression (TRD) NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“at |
Insider Buying: Florian Brand Acquires 40,000 Shares of ATAI Life Sciences NVOn September 13, 2023, Florian Brand, See Remarks at ATAI Life Sciences NV (NASDAQ:ATAI), made a significant purchase of 40,000 shares of the company's stock. |
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare ConferenceNEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference. Details of the company’s participation is as follows: 2023 Cantor Fitzgerald Global Healthcare Conference Format: Fireside Chat Date and Time: Thursday, September 28th at 1:50 P.M. ET Location: New York, NY A webcast o |
atai Life Sciences to Participate in Upcoming September Investor ConferencesNEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences. Details of the company’s participation are as follows: Citi's 18th Annual BioPharma Conference Format: 1x1 Only Date: Thursday, September 7th Location: Boston, MA H.C. Wainwright 25th Annual Global Investment Conference Format: Firesi |
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with SchizophreniaDMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof-of-concept study in patients with Opioid Use DisorderThe Company’s $227M cash position and committed term loan funding is expected to fund operations into 1H 2026 NEW YORK and BERLIN, Aug. 10, 2023 (GLOBE NEWSWIRE |